Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PROCEPT BioRobotics Corporation - Common Stock (NQ:PRCT)

32.97 -0.97 (-2.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about PROCEPT BioRobotics Corporation - Common Stock

< Previous 1 2 3 Next >
PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
Japanese post market survey supports safety and efficacy of Aquablation therapy 
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
Presentations include first published experience report of same-day discharge in an ambulatory surgical center, real-world data outcomes and 5-year data comparison between two FDA trials 
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023
From PROCEPT BioRobotics
Via GlobeNewswire
The National Institute for Health and Care Excellence Endorses Aquablation® Therapy with "Standard Arrangements" Recommendation
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Announces New Corporate Headquarters in San Jose
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate Cancer
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in Boston
From PROCEPT BioRobotics
Via GlobeNewswire
NorthShore University HealthSystem offers expanded access to treat most common prostate ailment
Highland Park Hospital adds second AquaBeam system, Swedish Hospital installs first 
From PROCEPT BioRobotics; NorthShore University HealthSystem
Via GlobeNewswire
PROCEPT BioRobotics Corporation Announces Pricing of Upsized Offering of Common Stock
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Reports Second Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report Second Quarter 2023 Financial Results on July 27, 2023
From PROCEPT BioRobotics
Via GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against PROCEPT BioRobotics Corporation and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Five-Year Data from the WATER II Study Demonstrate Aquablation Therapy Delivers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms while Preserving Sexual Function in Men with Large Prostates
From PROCEPT BioRobotics
Via GlobeNewswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PROCEPT BioRobotics Corporation and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
PROCEPT BioRobotics Reports First Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report First Quarter 2023 Financial Results on April 27, 2023 and Present at the Bank of America 2023 Health Care Conference in Las Vegas
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Corp. Announces Investor Event at 2023 AUA Annual Meeting in Chicago
From PROCEPT BioRobotics
Via GlobeNewswire
Aquablation Therapy is the first surgical robotics system to receive a MedTech Innovation Briefing (MIB) from the National Institute for Health Care Excellence
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Corp. to Present at the Virtual Key Bank Life Sciences & MedTech Investor Forum
From PROCEPT BioRobotics
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.